Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7232MR)

This product GTTS-WQ7232MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7232MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12830MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ5927MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ13473MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ8917MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ2851MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ5822MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ14644MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ10147MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LBR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW